This site requires Javascript.

Please enable Javascript before proceeding:

Firefox

  1. In the FireFox address bar, type about:config.
  2. Look for the javascript.enabled setting.
  3. Set it to true by right-clicking and pressing toggle.

Internet Explorer

  1. On the Tools menu, click Internet Options, then click the Security tab.
  2. Click the Internet Zone.
  3. If you do not have to customize your Internet security settings, click Default Level. Then do step 4.
  4. If you have to customize your Internet security settings, follow these steps:
    a. Click Custom Level.
    b. In the Security Settings - Internet Zone dialog box, click Enable for Active Scripting in the Scripting section.
  5. Click the Back button to return to the previous page, and then click the Refresh button to run scripts.

Chrome

  1. In the Chrome address bar, type chrome://settings/content/javascript.
  2. Adjust the toggle so that javascript is allowed.
  3. Close the Settings tab and Refresh the page.

 

Pre-Conference Program - Respirology Year in Review CME Evening

The Pre-Conference Registration event includes a three course meal which will be served throughout the evening starting at 7:00 pm.

The Year in Review will focus on Pulmonary Hypertension (PH) and COPD. The session on PH will update physicians on Group 3 PH and review diagnostic and management dilemmas in this area. The session on COPD will update physicians on the latest important clinical research in COPD and how to apply these results to patient care.

TIME PROGRAM TITLE
1800 Registration
1910 Welcome
John Thenganatt, CME Director, Division of Respirology, University of Toronto
1915 Group 3 Pulmonary Hypertension - Update
Dr. John Granton, Division of Respirology, University Health Network, University of Toronto
1945 Q & A
2015 COPD Research Update
Dr. Matthew Stanbrook, Division of Respirology, University Health Network, University of Toronto
2045 Q & A

Main Conference Program - University of Toronto Update in Interstitial Lung Diseases

The UofT Annual Day in Respirology is a one-day conference offering an interactive program focusing on the assessment and treatment of ILD in adults. After attending the Annual Day in Respirology, participants will be able to apply evidence-based, updated information in the assessment, testing and treatment of patients with ILD.

TIME PROGRAM TITLE SPEAKER
07:30 Registration and Breakfast
08:00 Division Director's Message CW. Chow
08:05 Introduction to Conference App and Passport J. Thenganatt
08:15 Scientific Chair's Welcome S. Shapera

Session I Chair: S. Shapera
08:20 A Practical Guideline-Based Approach to Diagnosis of Hypersensitivity Pneumonitis A. Lau
08:45 Non-UIP Radiographic PatternsM. McInnis
09:10 Update in Advanced Diagnostic Testing in ILD J. Fisher
09:35 Q & A with Panel A. Lau, M. McInnis, J. Fisher
10:00 Break

Session IIChair: A. Youn
10:30 The ACR/CHEST Guidelines: Treatment of SARD-ILD S. Johnson
11:00 ILD Exacerbations – Diagnosis and Treatment L. Fidler
11:20 Pulmonary Sarcoidosis in 2024M. Balter
11:40 Q & A with PanelS. Johnson, L. Fidler, M. Balter
12:05 Lunch Break

Session III Chair: J. Fisher
13:20 Keynote Speaker: Genetics, Genomes and Biomarkers - Past, Present, and Future A. Adegunsoye
13:50 Checkpoint Inhibitor Pneumonitis S. Shapera
14:15 Q & A with Panel A. Adegunsoye, S. Shapera
14:35 Break
Session IV Chair: L. Fidler
14:50 Symptom Management and MAID R. Colman
15:10 Transplant in the ILD Patient: How do age, BMI, esophageal disease and Coronary Artery Disease Impact Candidacy and Outcomes M. Binnie
15:30 Q & A R. Colman, M.Binnie
15:55 Let’s Stick to the FAQs: A Case-Based Panel Discussion A. Adegunsoye, J. Fisher, S. Shapera
16:25 Closing Remarks J. Thenganatt

Learning Objectives for the 5th Annual Year in Review CME Evening (Pre-Conference Evening Event)

The 5th Annual Year in Review will focus COPD and Pulmonary Hypertension

  • After the session on COPD, participants will be able to list the most important clinical research in COPD over the past twelve months. Participants will be to apply new therapies for the treatment of COPD. Participants will be able to integrate this new information into their management approach of asthma patients
  • After the session on Pulmonary Hypertension, participants will be able to: Demonstrate a practical evidence-informed approach to diagnosing and treating patients with pulmonary hypertension in the context of chronic lung disease.

Learning Objectives for the University of Toronto 15th Annual Day in Respirology

A. Overall Event:

  • The UofT Annual Day in Respirology is a one-day conference offering an interactive program focusing on the assessment and treatment of ILD in adults. After attending the Annual Day in Respirology, participants will be able to apply evidence-based, updated information in the assessment, testing and treatment of patients with ILD.

B. Specific Sessions:

  • After the session on Hypersensitivity Pneumonitis, participants will be able to:
    • Differentiate between fibrotic and non-fibrotic chronic hypersensitivity pneumonitis
    • Take a relevant history of different classes of organic exposures in a patient with suspected hypersensitivity pneumonitis
    • Incorporate guideline-based CT scan classification into their diagnostic algorithm in patients with suspected hypersensitivity pneumonitis
    • Assess the need for ancillary testing [bronchoscopy, transbronchial and surgical lung biopsy] in patients with suspected hypersensitivity pneumonitis
    Reference:
    • Raghu G, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Aug 1:202(3):e36-e69.
  • After the session on Non-UIP Radiographic Patterns, participants will be able to:
    • Recognize and describe the radiographic patterns of patients with a variety of diffuse parenchymal lung diseases that do not fit into the “usual interstitial pneumonia” category
    • Appreciate the differences between different radiographic patterns such as chronic hypersensitivity pneumonitis (cHP), non-specific interstitial pneumonitis (NSIP), organizing pneumonia (OP), diffuse alveolar damage pattern (DAD), acute fibrinous organizing pneumonia (AFOP), pleuroparenchymal fibroelastosis (PPFE), cystic lung diseases and nodular lung diseases including respiratory bronchiolitis (RB), langerhaans cell histiocytosis (LCH) and sarcoidosis.
    Reference:
    • Travis WD, et al. An official American Thoracic Society / European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15:188(6):733-48.
  • After the session on update in advance of diagnostic testing in ILD, participants will be able to:
    • Assess the role of genomic classifiers, optical coherence tomography and other emerging diagnostic tests in helping establish a diagnosis in patients with unclassified interstitial lung disease
    Reference:
    • Kheir F, et al. Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2022 May:19(5):827-832.
    • Nandy S, et al. Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia. Am J Respir Crit Care Med. 2021 Nov 15;204(10):1164-1179.
  • After the session on ACR/CHEST Guidelines: Treatment of Systemic Autoimmune Rheumatic Disorders (SARD) associated Interstitial Lung Disease, participants will be able to:
    • Prioritize first and second line therapies for a variety of auto-immune lung diseases
    • Appreciate the differences in recommendations for therapy between different auto-immune lung diseases
    Reference:
    • Johnson SR, et al. 2023 American College of Rheumatology (ACR) / American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024 Aug;76(8):1182-1200.
    • Raghu G, et al. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024 Jan 15;209(2):137-152.
  • After the session on ILD Exacerbations – Diagnosis and Treatment, participants will be able to:
    • Summarize the diagnostic workup of a patient with a suspected ILD exacerbation
    • Confirm the randomized control trial data against the use of cyclophosphamide in ILD exacerbations
    Reference:
    • Collard H, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75.
    • Naccache JM, et al. Cyclophosphamide added to gluclocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022 Jan;10(1):26-34.
  • After the session on Pulmonary Sarcoidosis in 2024, participants will be able to:
    • Review different radiographic patterns that have been associated with sarcoidosis
    • Summarize the latest treatment guidelines for pulmonary sarcoidosis
    Reference:
    • Desai SR, et al. High Resolution CT phenotypes in pulmonary sarcoidosis: a multi-national Delphi consensus study. Lancet Respir Med. 2024 May; 12(5):409-418.
    • Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021 Dec 16;58(6):2004079.
    After the session on Genetics, Genomics and Biomarkers – Past, Present, and Future, participants will be able to:
    • Summarize the latest developments in the pathobiology of ILD and how this may impact future management of ILD
    Reference:
    • Adegunsoye A, et al. Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Am J Respir Crit Care Med. 2024 Apr.4. [online ahead of print]
  • After the session on Checkpoint Inhibitor Pneumonitis, participants will be able to:
    • Summarize the risk factors for and radiographic presentations of checkpoint inhibitor pneumonitis
    • Understand the role of different immunosuppressive agents in severe checkpoint inhibitor pneumonitis
    • Appreciate the differences between steroid-resistant and steroid-refractory checkpoint inhibitor pneumonitis and how this impacts treatment decisions
    Reference:
    • Haanen J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow up. Ann Oncol. 2022 Dec;33(12):1217-1238.
    • Brahmer J, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor related adverse events. Journal for ImmunoTherapy of Cancer 2021;Jun; 9(6):e002435
  • After the session on Symptom Management and MAID, participants will be able to:
    • Understand the competing risks and benefits of narcotic based cough suppressants in patients with idiopathic pulmonary fibrosis
    • Prioritize patient reported outcomes and quality of life in patients living with ILD
    • Navigate the evolving landscape, indications, contraindications and process to access of medical assistance in dying in Ontario
    Reference:
    • Wu Z, et al. PAciFy Cough – a multicenter, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough
  • After the session on Transplant in the ILD Patient: How do age, BMI, Esophageal Disease and Coronary Artery Disease Impact Candidacy and Outcomes, participants will be able to:
    • Communicate the unique risks for lung transplant in patients over age 70
    • Optimize comorbid conditions including BMI, esophageal disease and coronary artery disease in potential lung transplant candidates to increase their likelihood of listing and successful post-operative outcomes
    Reference:
    • Zhou AL, et al. Outcomes of Lung Transplant Candidates Aged ≥ 70 Years During the Lung Allocation Score Era. Ann Thorac Surg. 2024 Apr;117(4):725-732
  • After the session on Let’s Stick to the FAQs: A Case-Based Panel Discussion, participants will be able to:
    • Debate controversial topics in the diagnosis and treatment of ILD
    • Evaluate the safety of anti-fibrotic drugs in patients with chronic liver and kidney disease
    • Optimize the timing of initiation of anti-fibrotic therapy in IPF and non-IPF progressive pulmonary fibrosis

Register

Event Dates

Pre conference
November 7, 2024

Main Conference
November 8, 2024

Event Location

Pan Pacific Hotel
900 York Mills Rd, North York, ON

Information

Registration Inquiries
conferences@uhn.ca
Click here to subscribe to our communications list.

Cancellation Policy

A full refund, minus a 25% administration fee, will be issued for cancellations received via e-mail to conferences@uhn.ca on or before October 11th, 2024. No refunds will be issued after this date. Refunds will not be granted to registrants who do not attend the conference or for cancellations to the preconference.  Refunds will not be issued for the Pre-Conference.